Literature DB >> 16322188

Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy.

.   

Abstract

Duchenne muscular dystrophy is the most common and severe form of the childhood muscular dystrophies. The disease is typically diagnosed between 3 and 7 years of age and follows a predictable clinical course marked by progressive skeletal muscle weakness with loss of ambulation by 12 years of age. Death occurs in early adulthood secondary to respiratory or cardiac failure. Becker muscular dystrophy is less common and has a milder clinical course but also results in respiratory and cardiac failure. The natural history of the cardiomyopathy in these diseases has not been well established. As a result, patients traditionally present for cardiac evaluation only after clinical symptoms become evident. The purpose of this policy statement is to provide recommendations for optimal cardiovascular evaluation to health care specialists caring for individuals in whom the diagnosis of Duchenne or Becker muscular dystrophy has been confirmed.

Entities:  

Mesh:

Year:  2005        PMID: 16322188     DOI: 10.1542/peds.2005-2448

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  44 in total

1.  Exercise-induced left ventricular systolic dysfunction in women heterozygous for dystrophinopathy.

Authors:  Robert M Weiss; Richard E Kerber; Jane K Jones; Carrie M Stephan; Christina J Trout; Paul D Lindower; Kimberly S Staffey; Kevin P Campbell; Katherine D Mathews
Journal:  J Am Soc Echocardiogr       Date:  2010-06-19       Impact factor: 5.251

2.  Factors affecting the health-related quality of life of caregivers of patients with muscular dystrophy.

Authors:  Yi-Jing Lue; Shun-Sheng Chen; Yen-Mou Lu
Journal:  J Neurol       Date:  2018-04-26       Impact factor: 4.849

3.  AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice.

Authors:  Brian Bostick; Jin-Hong Shin; Yongping Yue; Dongsheng Duan
Journal:  Mol Ther       Date:  2011-08-02       Impact factor: 11.454

4.  Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy.

Authors:  Elizabeth M McNally; Jonathan R Kaltman; D Woodrow Benson; Charles E Canter; Linda H Cripe; Dongsheng Duan; Jonathan D Finder; William J Groh; Eric P Hoffman; Daniel P Judge; Naomi Kertesz; Kathi Kinnett; Roxanne Kirsch; Joseph M Metzger; Gail D Pearson; Jill A Rafael-Fortney; Subha V Raman; Christopher F Spurney; Shari L Targum; Kathryn R Wagner; Larry W Markham
Journal:  Circulation       Date:  2015-05-05       Impact factor: 29.690

5.  Case 1: Back pain in a boy with Duchenne muscular dystrophy.

Authors:  Iskra Peltekova; Michael Storr
Journal:  Paediatr Child Health       Date:  2014-06       Impact factor: 2.253

6.  Myocardial Fibrosis and Left Ventricular Dysfunction in Duchenne Muscular Dystrophy Carriers Using Cardiac Magnetic Resonance Imaging.

Authors:  Sean M Lang; Svetlana Shugh; Wojciech Mazur; Joshua J Sticka; Mantosh S Rattan; John L Jefferies; Michael D Taylor
Journal:  Pediatr Cardiol       Date:  2015-05-16       Impact factor: 1.655

Review 7.  Duchenne muscular dystrophy: the management of scoliosis.

Authors:  James E Archer; Adrian C Gardner; Helen P Roper; Ashish A Chikermane; Andrew J Tatman
Journal:  J Spine Surg       Date:  2016-09

8.  Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy.

Authors:  Nalinda B Wasala; Brian Bostick; Yongping Yue; Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2013-03-03       Impact factor: 6.150

Review 9.  Pediatric heart failure therapy with beta-adrenoceptor antagonists.

Authors:  Susan R Foerster; Charles E Canter
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

10.  The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used.

Authors:  Craig M McDonald; Erik K Henricson; R Ted Abresch; Jay J Han; Diana M Escolar; Julaine M Florence; Tina Duong; Adrienne Arrieta; Paula R Clemens; Eric P Hoffman; Avital Cnaan
Journal:  Muscle Nerve       Date:  2013-05-16       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.